Cardiff Oncology Inc. (CRDF)
Market Closed
16 Oct, 08:00 PM
$
0. 90
-0.07
-7.1988%
$
83.24M Market Cap
- P/E Ratio
- Div Yield
515,538 Volume
- Eps
$ 0.97
Previous Close 
Want to track CRDF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC. Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response rates, and extends progression-free survival. Ongoing Phase 2 trials for Onvansertib in various cancers include collaborations with Pfizer and other prestigious institutions.
Seekingalpha | 2 years ago
2026 © Marketlog. All Rights Reserved.
